CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
8mg galantamine twice dailyfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02872857
NCT02872857Phase 2Completed
CompareCT.gov

A Pilot Parallel Double-Blind, Randomized Trial of Galantamine for Subarachnoid Hemorrhage

The University of Texas Health Science Center, Houston·interventional·Posted Aug 19, 2016·Updated Oct 8, 2021

In Brief

A Phase 2 clinical trial evaluating Placebo, 8mg galantamine twice daily, and 1 other intervention for Subarachnoid Hemorrhage. Completed, enrolled 60 participants across 2 sites.

Detailed Summary

The purpose of this study is to examine the effects of the study drug--Galantamine-on patients with subarachnoid hemorrhage (SAH). The study will examine how patients with SAH will tolerate the study drug and how it may improve brain functioning in patients after SAH.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubarachnoid Hemorrhage
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 19, 2016
Enrollment StartSep 1, 2016
Primary CompletionJul 20, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 9.9 years ago

Interventions

Placebodrug

Placebo will match drug capsules.

8mg galantamine twice dailydrug

Drug will be administered within 36 hours of hospitalization and continued for 90 days.

12mg galantamine twice dailydrug

Drug will be administered within 36 hours of hospitalization and continued for 90 days.